
    
      The objective is to assess the efficacy and safety of 0.002% and 0.05% difluprednate
      ophthalmic emulsions in patients with postoperative inflammation after cataract surgery
      (implantation of intraocular lens). In addition, the evaluation system for a future
      dose-finding phase III study of difluprednate ophthalmic emulsion will be established.
    
  